


# Financial update

**Ron Wirahadiraksa**  
CFO Royal Philips

# Macro-environment continues to be challenging

## Annual global growth in %

■ Actual ■ 2014 Forecast ■ 2015 Forecast



- Outlook remains fragile
- Growth geographies deteriorating:
  - Russia and Brazil declining
  - China <7%
- Negative impact of USD
- Flat capex and construction spending in the US in 2015<sup>3</sup>
- Healthcare construction +3.8% in Europe in 2015 and +0.8% in 2016<sup>2</sup>
- Mature markets outlook down, including US and Germany
- Slowdown in China and contraction in Brazil and Russia
- +1.8% in the US and +2.2% in Europe in 2015

<sup>1</sup> Source: Economist Intelligence Unit. <sup>2</sup> Source: IHS Global Insights. <sup>3</sup> Source: McGraw-Hill.

# Managing through deteriorating environment in growth geographies

## Significant slowdown seen in China, Brazil and Russia

Combined, these markets represent ~15% of revenues, with China ~10%

### China

#### Current challenges

- Macroeconomic slowdown, weak construction market
- Anti-corruption measures, efforts to promote domestic innovation and centralized tendering in healthcare


#### Addressing challenges and improving long-term positioning

- Driving further efficiency, competitive cost structure
- Continue to invest in innovation and pockets of growth
- Focus on new market opportunities (e.g. private healthcare sector, fast-growing Health & Wellness business)
- Driving solutions, new business models and strategic partnerships

#### Market outlook

- Healthcare and lighting markets expected to be subdued in H2 2015; gradual improvement expected in 2016
- Consumer Lifestyle businesses experiencing slower growth

# Accelerate! improved operational performance and offset headwinds in H1 2015



<sup>1</sup> Net effect of currency impact on sales and EBITA.

# Trading update and outlook H2 2015

## Factors positively impacting H2

- Cost savings programs and Excellence
- Good order backlog
- Cleveland production ramp-up
- Lower restructuring costs vs. LY
- Gradual improvement in Professional Lighting Solutions North America


## Factors negatively impacting H2

- Slowdown in growth geographies, especially China
- Currency impact on EBITA margin
- Remaining separation costs of EUR 160 - 260 million<sup>1</sup>
- Pension de-risking

*We continue to expect modest comparable sales growth for 2015 and are focused on improving the adjusted EBITA margin compared to 2014*

<sup>1</sup> Difference between guidance for FY 2015 of EUR 200-300 million and actual expenditure of EUR 40 million in H1 2015.

# Recent currency developments lead to unfavorable impact for 2015



## Summary of net position


- Short position in USD
  - Short in Q1-Q3 and long in Q4 due to sales seasonality
  - USD footprint has changed; most notably by the intended sale of Lumileds/Automotive and Volcano acquisition
- Long in growth geographies' currencies (not entirely hedged): IDR, BRL, INR, RUB, etc.

## EBITA impact in H2 2015 now expected to be slightly negative

Change vs. previous expectation is mostly driven by RUB, IDR, TWD and THB

**Despite an expected positive EBITA margin impact in Q4, the FY 2015 impact is now expected to be negative**

# Operational improvements offset macro risks and headwinds



*We expect modest comparable sales growth and are focused on driving further operational EBITA improvement in 2016, while also investing in growth*

Note: Prior-period financials have been restated for the treatment of the combined businesses of Automotive and Lumileds as discontinued operations.

# Productivity programs continue to improve operational performance

<i>(EUR million)</i>	<b>2014</b>	<b>2015</b>	<b>2016</b>
Incremental gross overhead cost savings in the period	284	265	200
Procurement	284	~300	~400
End2End productivity gains	79	~80	~90
Restructuring and investments <sup>1</sup>	(240)	(260)	(190)

*All savings numbers are gross numbers*




<sup>1</sup> Investments to enable overhead cost savings as well as on the overall execution of the *Accelerate!* transformation.



# Operational improvement will drive ROIC growth

## Return on Invested Capital (%)<sup>1</sup>



### Strong progress towards structural ROIC improvement

- 2014 and H1 2015 impacted by incidentals
- ROIC expected to be >12% by 2016
- *Accelerate!* as a key enabler

<sup>1</sup> ROIC is EBIAT/NOC; NOC is average over the last 5 quarters. EBIAT is the sum of the last 4 quarters' earnings before interest after tax; reported tax used to calculate EBIAT.

# Our businesses have strong cash conversion capabilities; driving further improvement

## Driving structural improvements in working capital

---

- Philips Excellence, factory LEAN deployment (52% of sites covered by 2016)
- Philips Capital for specific services and solutions in growth geographies
- Partnering with suppliers to optimize trade payables

## Capex needs will decrease over time


---

- Conventional lighting footprint optimization
- Significant part of HealthTech businesses are trending towards an assembly & testing model
- Divestment of capex-intensive businesses (Lumileds/Automotive)

# The separation is on track

- Complex separation of highly-integrated operations
- Creating optimal infrastructure for two fit-for-purpose operating companies
- Critical major milestones have been reached
  - Most new legal entities incorporated
  - Completed organizational separation
  - Separated assets and liabilities of IG&S
- Next steps
  - Separate and optimize IT systems
  - Philips Lighting own legal structure by February 2016
  - New external reporting structure from Q1 2016 onwards
  - Execute capital market access: reviewing all strategic options for Philips Lighting

# New reporting structure from Q1 2016 onwards



Personal Care	Health & Wellness	Diagnostic Imaging	Patient Care & Monitoring Sol.	Royalties	Conventional lamps	Legacy litigation
Domestic Appliances	Personal Health Solutions	Ultrasound	Healthcare Informatics, Sol. & Services	Central research	LED lamps, drivers & modules	Separation cost
	Sleep & Respiratory Care	Image-Guided Therapy		Emerging businesses	Professional Lighting Solutions	Stranded cost
					Home	
					Other	

Focus of external reporting

Historical pro-forma comparable numbers under new reporting structure will be provided prior to the Q1 2016 results publication

<sup>1</sup> Corporate items not related to Lighting.

# IG&S split

## % of IG&S revenues/cost split – 2015E

	HealthTech	Lighting	Corporate items
Revenue - IP Royalties	100%	-	-
Cost - innovation, overhead and service units	85%	15%	-
Other/legacy	-	-	~100%

## % of IG&S EBITA split – 2015E

	HealthTech	Lighting	Corporate items
Adjusted EBITA	45%	35%	20%
Reported EBITA	25%	25%	50%

- IG&S split results in a ~1.3% negative reported EBITA margin impact for HealthTech and ~2.4% for Lighting<sup>1</sup>
- Current IG&S revenues and costs expected to decline over time, due to declining license revenues and lower cost expenditure
- Corporate items not allocated to the two operating companies represent ~1% of Group sales

<sup>1</sup> Based on FY 2015E numbers.

# Creating two fit-for-purpose companies with a strong foundation for value creation

## Right operating model and competitive cost structure

- Philips Business System to drive value creation
- Single value-added layer enables cost savings and faster decision-making
- Philips Excellence, Continuous Improvement (LEAN)

## Drive value creation from market opportunities and execution of strategic priorities

- Appropriate infra-structure to enable new business models: Solutions organization, IT backbone, Philips Capital, risk management framework
- Complete Volcano integration and realize synergies
- Increase cash efficiency to fund growth and innovation

## Appropriate share of assets and liabilities

- Balance sheet for both operating companies to be provided from Q1 2016 onwards
- Until completion of the separation:
  - Other liabilities will be split based on originating entity
  - Existing debt reported under Royal Philips
  - Majority of DTA<sup>1</sup> reported under Royal Philips

<sup>1</sup> Deferred Tax Assets.

# Capital allocation

- Continue to invest in high ROIC organic growth opportunities to strengthen each business
- Disciplined but more active approach to M&A, with a focus on HealthTech, while continuing to adhere to strict return hurdles
- Committed to a strong investment grade credit rating
- Committed to dividend-stability and a 40% to 50% pay-out of continuing net income
- Complete the current EUR 1.5 billion share buyback program by October 2016

# Key takeaways

- Challenging macro-environment, deterioration in certain growth geographies and unfavorable FX developments are impacting performance
- **Accelerate! program** continues to drive operational performance improvements
- Operational improvements support **modest CSG and ~11% adjusted EBITA in 2016**
- **Separation process** to create two fit-for-purpose companies is **on track**
- Move to **new reporting structure** from Q1 2016 onwards





